Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• The safety profile of perfluorohexyloctane was noted as effective and safe, though specific details on adverse events were not provided.
• Ocular treatment-emergent adverse events (TEAES) were fewer in the perfluorohexyloctane group compared to controls the mean difference (MD) was -0.66 ± 1.7, suggesting good tolerability of the drug.
• The safety profile was mentioned as safe, though specific details regarding adverse events were not provided.
• Perfluorohexyloctane was associated with fewer ocular treatment-emergent adverse events (MD = -0.66 ± 1.7) compared to control, indicating satisfactory tolerability.
• The studies focused on patients with Meibomian Gland Dysfunction (MGD) and evaporative dry eye disease (DED). There were no specific subgroup analyses or further population-specific findings provided.